 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | lenalidomide (STAR-LLD SC) / Starton Therap
New P1/2 trial: Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) (clinicaltrials.gov) - Oct 17, 2023
P1/2, N=6, Recruiting, Sponsor: Starton Therapeutics, Inc
- lenalidomide (STAR-LLD SC) / Starton Therap
Activity and tolerability of lenalidomide (LLD) is enhanced following low-dose continuous percutaneous delivery compared to once daily dosing in an NCIH929 MM Xenograft model in SCID mice () - Aug 13, 2022 - Abstract #IMW2022IMW_349;
A percutaneous delivery of just 29% of the standard i.p. LLD dose was superior in disease control and can produced objective responses in this model. Tolerability in terms of body weight, histopathology, and hematology suggest no aberrant effects from continuous delivery.